von Willebrand factor is a major determinant of ADAMTS-13 decrease during mouse sepsis induced by cecum ligation and

N Lerolle1, C Dunois-Lardé, I Badirou

  • 1Service de Réanimation Médicale, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.

Abstract

Insights

Sepsis increases von Willebrand factor (VWF), leading to decreased ADAMTS-13 activity. While VWF impacts sepsis mortality, manipulating ADAMTS-13 levels did not alter survival outcomes in this study.

Area of Science:

  • Hematology
  • Critical Care Medicine
  • Molecular Biology

Background:

  • Sepsis involves abundant secretion of von Willebrand factor (VWF).
  • ADAMTS-13, a metalloprotease, regulates VWF size through proteolysis.
  • Understanding the interplay between VWF and ADAMTS-13 in sepsis is crucial.

Purpose of the Study:

  • To investigate if ADAMTS-13 consumption, due to VWF binding and cleavage, causes its decrease during sepsis.
  • To determine if altering ADAMTS-13 activity affects sepsis outcomes.

Main Methods:

  • Cecum ligature and puncture (CLP) model of sepsis in wild-type, Vwf(-/-), and Adamts-13(-/-) mice.
  • Evaluation of ADAMTS-13 activity and VWF levels.
  • Assessment of sepsis outcomes, including survival and thrombocytopenia.
  • Hydrodynamic gene transfer to enhance ADAMTS-13 activity in wild-type mice.

Main Results:

  • Sepsis in wild-type mice significantly decreased ADAMTS-13 activity, correlating negatively with VWF levels.
  • In Vwf(-/-) mice, sepsis severity was high, but ADAMTS-13 levels remained stable; these mice showed improved survival.
  • Complete absence of ADAMTS-13 did not alter sepsis-induced thrombocytopenia, VWF concentrations, or survival compared to wild-type mice.
  • Enhanced ADAMTS-13 activity via gene transfer did not improve survival in CLP-induced sepsis.

Conclusions:

  • VWF secretion significantly contributes to ADAMTS-13 decrease in sepsis and influences mortality.
  • Complete deficiency of ADAMTS-13 had no discernible impact on the sepsis model.
  • Augmenting ADAMTS-13 activity did not improve survival rates in sepsis.